Immunotherapy of oneiric stupor in Morvan syndrome: Efficacy documented by actigraphy

Simone Baiardi, Federica Provini, Patrizia Avoni, Marco Pasquinelli, Rocco Liguori

Research output: Contribution to journalArticlepeer-review


Morvan syndrome (MoS) is a rare acquired channelopathy associated with autoantibodies against potassium channel complex and clinically characterized by the heterogeneous combination of neuromyotonia, dysautonomia, and encephalopathy.1 Peculiar CNS symptoms are organic insomnia, which ranges from mild to malignant forms characterized by complete loss of sleep, and persistent motor/autonomic hyperactivation (agrypnia excitata2). We describe a patient with MoS who developed progressive agrypnia excitata, in which IV immunoglobulin (IVIg) treatment induced a progressive recovery of the physiologic sleep-wake cycle, documented by videopolysomnography (VPSG) and actigraphic monitoring.

Original languageEnglish
Pages (from-to)2457-2459
Number of pages3
Issue number24
Publication statusPublished - Jun 16 2015

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Immunotherapy of oneiric stupor in Morvan syndrome: Efficacy documented by actigraphy'. Together they form a unique fingerprint.

Cite this